4.7 Article

Organoids Model Transcriptional Hallmarks of Oncogenic KRAS Activation in Lung Epithelial Progenitor Cells

Journal

CELL STEM CELL
Volume 27, Issue 4, Pages 663-+

Publisher

CELL PRESS
DOI: 10.1016/j.stem.2020.07.022

Keywords

-

Funding

  1. Boehringer Ingelheim Fonds PhD fellowship
  2. NIH R01 postdoctoral supplement
  3. Damon Runyon Cancer Research Foundation postdoctoral fellowship [DRG:2368-19]
  4. Postdoctoral Enrichment Program Award from the Burroughs Wellcome Fund
  5. Hope Funds for Cancer Research postdoctoral fellowship
  6. IASLC Young Investigator Fellowship
  7. American Cancer Society Research Scholar Grant [RSG08-082-01-MGO]
  8. V Foundation for Cancer Research
  9. Thoracic Foundation
  10. Ellison Foundation
  11. American Lung Association [LCD-619492]
  12. Harvard Stem Cell Institute
  13. Lung Cancer Initiative at Johnson Johnson
  14. Boston University
  15. Stand Up To Cancer-LUNGevityAmerican Lung Association Lung Cancer Interception Dream Team translational cancer research grant [SU2C-AACR-DT23-17]
  16. American Association for Cancer Research, the scientific partner of SU2C
  17. NIH/NCI Molecular Characterization Laboratory [5U01CA196408-04]
  18. UC TobaccoRelated Disease Research Program (TRDRP) [27IR-0036]
  19. Thoracic Surgery Foundation research award
  20. [R01 HL090136]
  21. [R01 HL132266]
  22. [R01 HL125821]
  23. [U01 HL100402]
  24. [RFA-HL-09-004]
  25. [R35HL150876-01]
  26. [R24HL123828]
  27. [U01TR001810]
  28. [R01HL128172]
  29. [R01HL095993]
  30. [R01HL122442]
  31. [U01HL134745]
  32. [U01HL134766]

Ask authors/readers for more resources

Mutant KRAS is a common driver in epithelial cancers. Nevertheless, molecular changes occurring early after activation of oncogenic KRAS in epithelial cells remain poorly understood. We compared transcriptional changes at single-cell resolution after KRAS activation in four sample sets. In addition to patient samples and genetically engineered mouse models, we developed organoid systems from primary mouse and human induced pluripotent stem cell-derived lung epithelial cells to model early-stage lung adenocarcinoma. In all four settings, alveolar epithelial progenitor (AT2) cells expressing oncogenic KRAS had reduced expression of mature lineage identity genes. These findings demonstrate the utility of our in vitro organoid approaches for uncovering the early consequences of oncogenic KRAS expression. This resource provides an extensive collection of datasets and describes organoid tools to study the transcriptional and proteomic changes that distinguish normal epithelial progenitor cells from early-stage lung cancer, facilitating the search for targets for KRAS-driven tumors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available